Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue

A technology of cytidine analogs and drugs, which is applied in the field of immunology and molecular biology, and can solve problems that do not include antibodies

Pending Publication Date: 2020-05-08
VEB BERLIN CHEM
View PDF196 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the aforementioned combination therapy does not include antibody

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue
  • Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue
  • Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0408] Example 1: Construction of phage display library

[0409] A recombinant protein consisting of amino acids 29-292 of BST1 (SEQ ID NO:44) was eukaryotically synthesized by standard recombinant methods and used as antigen for immunization.

[0410] Immunization and mRNA isolation

[0411] A phage display library for the identification of BST1 binding molecules was constructed as follows. A / J mice (Jackson Laboratories, Inc., Bar Harbor, ME) were immunized intraperitoneally with recombinant BST1 antigen (extracellular domain) using 100 μg protein in Freund's complete adjuvant on day 0 and on day 28. Daily use of 100μg antigen. Test blood from mice was obtained via retro-orbital sinus puncture. If, by testing potency, use via Neutravidin (Reacti-Bind TM ) NeutrAvidin(TM)-coated polystyrene plates (Pierce Corporation, Rockford, IL) immobilized biotinylated BST1 antigen, and those titers were considered high by ELISA at days 70, 71 and 72 Mice were boosted with 100 [mu]...

Embodiment 2

[0446] Example 2: Selection of recombinant polyclonal antibodies against BST1 antigen

[0447] Binding reagents that specifically bind to BST1 were selected from a phage display library generated from hyperimmunized mice as described in Example 1.

[0448] panning

[0449] First-round antibody phage were prepared using the BS45 uracil template as described in Example 1. Electroporation of mutagenized DNA was performed to generate phage samples derived from different immunized mice. To generate greater diversity in recombinant polyclonal libraries, each phage sample was panned individually.

[0450] Antibody phage libraries were selected for phage displaying heavy and light chains on their surface by panning with 7F11-magnetic latex prior to the first round of functional panning with biotinylated BST1 antigen (as implemented in US 6,555,310 described in Examples 21 and 22). These enriched libraries were functionally panned in principle as described in Example 16 of US 6,5...

Embodiment 3

[0460] Example 3: Specificity of Monoclonal Antibodies to BST1 Determined by Flow Cytometry

[0461]The specificity of the antibodies against BST1 selected in Example 2 was tested by flow cytometry. To test the ability of the antibody to bind to cell surface BST1 protein, the antibody was incubated with BST1-expressing cells A549 and H226 from human lung adenocarcinoma and human lung squamous carcinoma, respectively. Cells were washed in FACS buffer (DPBS, 2% FBS), centrifuged and resuspended in 100 μl of diluted BST1 primary antibody (also diluted in FACS buffer). Antibody-A549 complexes were incubated on ice for 60 minutes and then washed twice with FACS buffer as described above. The cell-antibody pellet was resuspended in 100 μl of diluted secondary antibody (also diluted in FACS buffer) and incubated on ice for 60 minutes. Pellets were washed as before and resuspended in 200 μl FACS buffer. Samples were loaded onto a BD FACScanto II flow cytometer and data were analyze...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The disclosure relates to pharmaceutical combinations comprising antibodies against BST1 (ADP-ribosyl cyclase 2) together with a cytidine analogue or a pharmaceutically-acceptable salt thereof, and methods for the treatment of diseases, such as cancers mediated by BST1 (ADP-ribosyl cyclase 2) expression / activity and / or associated with abnormal expression / activity of BST1.

Description

[0001] preface [0002] The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein is a pharmaceutical combination comprising an antibody against BST1 (ADP-ribosyl cyclase 2) and a cytidine analog or a pharmaceutically acceptable salt thereof; and for the treatment of diseases, such as by BST1 (ADP - Method for cancers mediated by ribosyl cyclase 2) expression / activity and / or associated with aberrant expression / activity of BST1. Background technique [0003] Leukemias and lymphomas belong to a large group of tumors that affect the blood, bone marrow, and lymphatic system; these tumors are known as tumors of the hematopoietic and lymphoid tissues. [0004] Lymphomas are a group of blood cell tumors that develop from lymphocytes. Signs and symptoms include swollen lymph nodes, fever, lymphatic hyperhidrosis, involuntary weight loss, itching, and a constant feeling of tiredness. There are several subtypes of l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395C07K16/28A61P35/00
CPCA61K31/706A61K39/3955A61K45/06A61P35/00C07K16/2896C07K2317/24C07K2317/732C07K2317/77A61K2300/00C07K16/2809C07K2317/31C07K2317/41C07K2317/565
Inventor C·西蒙耐利A·贝拉卡尼M·比纳其D·贝拉罗萨C·卡利斯
Owner VEB BERLIN CHEM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com